Deputy Director of Nuclear Medicine Department, Chief Physician, Professor, Postdoctoral Supervisor
Affiliated HospitalPeking Union Medical College Hospital, Chinese Academy of Medical Sciences
→
Research areas: Comprehensive treatment and full-course management of thyroid cancer; treatment and molecular evolution mechanism of hypodifferentiated and undifferentiated thyroid carcinoma; integration of novel molecular probes with tumor diagnosis and treatment.
Cutting-edge technology: Pioneered internationally in applying RGD-type molecular probes reflecting tumor angiogenesis to localize iodine-refractory thyroid cancer; led domestic clinical trials of the proprietary targeted drugs apatinib and donafenib for the treatment of iodine-refractory thyroid cancer, demonstrating their efficacy. Served as the China coordinator for the IAEA RAS074 project.
Areas of expertise: Postoperative ¹³¹I treatment for differentiated thyroid cancer, diagnosis and treatment of iodine-refractory thyroid cancer, and Graves radionuclide therapy for hyperthyroidism.
Academic Highlights and Core Values: Chairman of the Thyroid Cancer Committee of the Chinese Society of Clinical Oncology (CSCO), and Chairman of the Thyroid Disease Committee of the China International Exchange and Promotion Association for Medical and Health Care. He holds a leading position nationwide in the field of radionuclide diagnosis and treatment of thyroid cancer, and promotes the international sharing of radionuclide diagnosis and treatment technologies.